US Officials to Correct Misinformation on Nicotine E-Cigarettes

Dec.13.2022
US Officials to Correct Misinformation on Nicotine E-Cigarettes
US tobacco researchers ask CDC for correct information on e-cigarettes, with health officials correcting misleading public health statements.

Tobacco researchers in the United States have consulted with the Centers for Disease Control and Prevention (CDC). The US Secretary of Health will address some incorrect information released by public health agencies regarding nicotine e-cigarettes.


US Health Secretary Vivek Murthy has recently launched an initiative to reduce the spread of health misinformation in light of the COVID-19 pandemic. As part of this effort, he has advised public health institutions such as the Centers for Disease Control and Prevention (CDC) to stop promoting inaccurate information about electronic cigarettes. For instance, the CDC had disseminated misleading information about the lung injuries caused by e-cigarettes in 2019 (EVALI), and the Health Secretary's report about youth e-cigarette use in 2016 had wrongly claimed that nicotine e-cigarettes were the most commonly used among young people.


The call was made in an editorial published in the Addiction journal. It was co-written by Michael Pesko, a health economist at Georgia State University, along with colleagues from Harvard Medical School, Pennsylvania State University, the Medical University of South Carolina and the University of Michigan. Tom Miller, the former chairman of the Truth Initiative board and Iowa's attorney general, was also a co-author.


The author of the editorial explained that the Center for Disease Control (CDC) named the lung injury of 2019 related to the usage of e-cigarettes as "EVALI" and refused to change the name, which led to widespread attention and misunderstanding from the public and scientific community about the cause of the disease.


It has been reported that the current director of the FDA's Center for Tobacco Products, Brian King, coined the term "EVALI." King is a staunch opponent of nicotine e-cigarettes and was formerly an employee in the smoking and health office at the Centers for Disease Control and Prevention.


The name EVALI has been indirectly responsible for the deaths of 68 people and has sent thousands to hospital, as they were not given a clear warning by public health officials about the risks associated with unregulated electronic cigarettes containing THC oil.


According to the author, all evidence indicates that the illegal tetrahydrocannabinol (THC) e-cigarettes contaminated with vitamin E acetate are the main risk factor for illness, but there is no research indicating any chemicals found in nicotine e-cigarettes. Vitamin E acetate is insoluble in nicotine e-liquid and has never been detected in nicotine e-cigarettes.


The author suggests that despite evidence to the contrary, the Center for Disease Control (CDC) continues to include e-cigarettes in the EVALI designation. This naming convention has had an impact on news reporting and has contributed to a distorted belief among consumers that using nicotine e-cigarettes is risky.


In 2021, the same author officially requested that the Centers for Disease Control and Prevention trace a change in the name "EVALI," removing "e-cigarette" from the name and adding "adult THC.


2FIRSTS will continue to report on this topic, with further updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Proposed vaping duty in Jersey: £467,000 forecast for 2026 as it takes effect in the second half of the year
Proposed vaping duty in Jersey: £467,000 forecast for 2026 as it takes effect in the second half of the year
Jersey is proposing a vaping duty. The Treasury Minister said the duty is forecast to raise £467,000 in 2026 because it will take effect in the second half of the year, and £955,000 per year from 2027 to 2029. Implementation is estimated to cost around £400,000 over four years, with an initial cost of £145,000 in 2026. The policy is described as aiming to reduce nicotine consumption and improve public health, while avoiding a shift to smoking.
Feb.26 by 2FIRSTS.ai
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
On March 27, 2026, PLONQ officially opened its upgraded Shenzhen office, reinforcing its long-term commitment to China and marking a new phase of growth. As a leading vape brand in Russia, PLONQ is expanding into new product categories while strengthening R&D, engineering collaboration, and partnerships with Chinese companies. The Shenzhen office will accelerate product development, enhance cooperation with technology and manufacturing partners, and support future growth initiatives.
Apr.01
Glas accuses FDA of ignoring its own science in e-cigarette product approval process
Glas accuses FDA of ignoring its own science in e-cigarette product approval process
Glas submitted G2 system PMTA in July 2021 for age verification device and 8 pod products, with FDA's mixed response.
Apr.23 by 2FIRSTS.ai
Imperial Tobacco Canada Responds to Anti-Smoking Groups on Youth Vaping
Imperial Tobacco Canada Responds to Anti-Smoking Groups on Youth Vaping
Imperial Tobacco Canada responded to the April 17 press conference by anti-smoking groups by calling for a more focused, fact-based discussion on youth vaping that targets the illicit market. The company said youth should not be using nicotine products and that it supports strong measures to prevent youth access, but argued that the discussion failed to clearly distinguish between the regulated market and the illicit market that is driving youth access.
Apr.22 by 2FIRSTS.ai
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai